Arshad M. Khanani, MD, MA, FASRS

Arshad M. Khanani, MD, MA, FASRS serves as the Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, as well as a Clinical Professor at the University of Nevada, Reno School of Medicine.

Articles by Arshad M. Khanani, MD, MA, FASRS

EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts

ByArshad M. Khanani, MD, MA, FASRS,Martin David Harp

October 4th 2026

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

EURETINA 2026: 2-year SPECTRA results and the phase 3 programme for 4D-150 gene therapy in DMO

ByArshad M. Khanani, MD, MA, FASRS,Martin David Harp

October 2nd 2026

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews 2-year SPECTRA data on 4D-150 gene therapy for DMO and the phase 3 4SIGHT trial comparing it with aflibercept.

ASRS 2026: Arshad M. Khanani, MD, MA, on SOL-1 phase 3 data

ByArshad M. Khanani, MD, MA, FASRS,Martin David Harp

July 17th 2026

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.